Home » Topics » Regulatory » EMA

EMA
RSS

Pergoveris recommended for E.U. approval

May 9, 2007

Ariad receives FDA feedback on pivotal study of AP-23573 for metastatic sarcoma

April 11, 2007

Lilly withdraws E.U. marketing authorization application for Arxxant

April 10, 2007

EMEA recommends restrictions on use of Ketek

April 4, 2007

Orencia recommended for approval in E.U. for rheumatoid arthritis

April 2, 2007

European CHMP hands down positive opinions for Xyrem and Prevenar

Jan. 30, 2007

Sprycel approved in E.U.

Dec. 1, 2006

Microdosing/phase 0 trials: Paradigm shift aims to speed new drug development, improve efficiency

Nov. 7, 2006

Aldara recommended for approval for actinic keratosis in Europe

Oct. 23, 2006

Positive opinion handed down in Europe for new Glivec indication

Oct. 23, 2006

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 17, 2026.
Dual FAAH/MAGL inhibition targets Alzheimer’s disease hyperexcitability
BioWorld Science
Reduced endocannabinoid signaling has been linked to neuronal hyperexcitability in Alzheimer’s disease (AD), suggesting that dual inhibition of fatty acid amide...
ALN-5288 lowers tau levels in preclinical models
BioWorld Science
Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....
Capital remains selective in ‘barbell’ biotech market
BioWorld
Signs of recovery are emerging in the biotechnology investment sector, although investors across Asia say that capital is flowing selectively to companies that...
PSB-229 reduces plaque burden in Alzheimer’s models
BioWorld Science
Pyroglutamate-modified amyloid-β (pE3-Aβ) is a highly pathogenic Aβ species that accumulates within amyloid plaques and contributes to aggregation,...